logo

SBRA

Sabra Health Care·NASDAQ
--
--(--)
--
--(--)
8.79 / 10
Outperform

Comprehensive analysis: strong fundamentals (8.8/10). Positive dimensions: PB-ROE and Income tax / Total profit (%), offset by weaknesses in Cash-UP and Net assets per share (growth rate compared to beginning of year %). Resulting position: highly favorable.

Fundamental(8.79)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-0.97
Score2/3
Weight18.98%
1M Return2.45%
Net assets per share (growth rate compared to beginning of year %)
Value-1.81
Score1/3
Weight-9.08%
1M Return-1.71%
Net income-Revenue
Value-0.21
Score2/3
Weight37.07%
1M Return3.99%
PB-ROE
Value-0.25
Score3/3
Weight67.73%
1M Return6.25%
Shareholders’ equity attributable to parent company (growth rate compared to beginning of year %)
Value3.05
Score0/3
Weight-11.01%
1M Return-1.98%
Income tax / Total profit (%)
Value1.04
Score2/3
Weight11.69%
1M Return1.54%
Cash-UP
Value-0.05
Score0/3
Weight4.22%
1M Return0.55%
Diluted earnings per share (YoY growth rate %)
Value55.88
Score0/3
Weight-6.87%
1M Return-1.07%
Asset-MV
Value0.10
Score2/3
Weight2.13%
1M Return0.61%
Cash-MV
Value-0.14
Score0/3
Weight-14.84%
1M Return-2.40%
Is SBRA undervalued or overvalued?
  • SBRA scores 8.79/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.61% ROE, 23.50% net margin, 26.03 P/E ratio, 1.68 P/B ratio, and 80.49% earnings growth, these metrics solidify its Outperform investment rating.